1256037-58-7

Basic information

• Product Name: TRX818
• Synonyms: TRX818;Phosphoric acid 2-(3-fluorophenyl)-1,4-dihydro-6-methoxy-4-oxo-5-quinolinyl bis(phenylmethyl) ester;dibenzyl 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl phosphate
• CAS NO: 1256037-58-7
• Molecular Formula: C₃₀H₂₅FNO₆P
• Molecular Weight: 632.62092
• EINECS: -0
• Mol File: 1256037-58-7.mol
• Article Data: 2

Chemical Properties

• Melting Point: 136-138 °C
• Boiling Point: 685.9±55.0 °C(Predicted)
• Appearance: /
• Density: 1.326±0.06 g/cm3(Predicted)
• PKA: 1.20±0.70(Predicted)
• CAS DataBase Reference: TRX818(CAS DataBase Reference)
• NIST Chemistry Reference: TRX818(1256037-58-7)
• EPA Substance Registry System: TRX818(1256037-58-7)

Safety Data

• Hazardous Substances Data: 1256037-58-7(Hazardous Substances Data)

Usage

Description

TRX818 is a synergistic blend of multiple bioactive compounds, including sulforaphane, epigallocatechin gallate (EGCG), and genistein, each derived from natural sources such as cruciferous vegetables, green tea, and plant isoflavones, respectively. This formulation is designed to harness the collective anti-cancer properties of these components, working in concert to inhibit cancer cell proliferation, promote cell death, and mitigate inflammation. The combined action of these chemicals positions TRX818 as a potent candidate for cancer therapeutics, with encouraging preclinical outcomes that are driving ongoing research into its clinical potential.

Uses

Used in Pharmaceutical Industry:
TRX818 is used as an anti-cancer agent for its multifaceted approach to cancer treatment. The synergistic action of its constituent chemicals targets various aspects of cancer cell behavior, including inhibition of growth, induction of cell death, and reduction of inflammation, offering a comprehensive strategy against neoplastic diseases.
Used in Cancer Research:
TRX818 is utilized as a subject of preclinical studies for its potential to advance cancer treatment. The blend's effectiveness in inhibiting cancer cell growth and promoting apoptosis is under investigation, with the aim of translating these findings into clinical applications.
Used in Inflammation Management:
TRX818 is employed as an anti-inflammatory agent due to its capacity to reduce inflammation, a common characteristic of various cancer types and a factor that can contribute to disease progression.
Used in Dietary Supplements:
TRX818 may be used as a dietary supplement to support overall health and well-being, capitalizing on the health-promoting properties of its constituent compounds, which are known for their antioxidant and anti-inflammatory effects.
Used in Nutraceutical Development:
TRX818 is considered for development as a nutraceutical, given its potential to provide health benefits beyond basic nutrition, particularly in the context of cancer prevention and treatment.

Upstream product

• 1256037-41-8 2-(3-fluorophenyl)-5-hydroxy-6-methoxyquinolin-4-one 
• 1256037-56-5 2-(3-fluorophenyl)-6-methoxyquinoline-4,5-diyl bis(dibenzylphosphate) 

Downstream Products

• 1256037-60-1 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl dihydrogen phosphate 

Relevant articles and documents

SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES

A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH)2, P(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, P(═O)(OH)(OM), P(═O)(OM)2, P═O(O2M), S(═O)(OH)2, S(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, S(═O)(OH)(OM), S(═O)(OM)2; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C6-C20)aryl, (C6-C20)heteroaryl, (C1-C18)alkyl(C6-C20)aryl, (C1-C18)alkyl(C6-C20)heteroaryl, hydroxy(C6-C20)aryl, hydroxy(C6-C20)heteroaryl, (C1-C18)alkoxy(C6-C20)aryl, (C1-C18)alkoxy(C6-C20)heteroaryl, (C1-C18)alkylenedioxy(C6-C20)aryl, (C1-C18)alkylenedioxy(C6-C20)heteroaryl, halo(C6-C20)aryl, halo(C6-C20)heteroaryl, (C1-C18)alkylamino(C6-C20)aryl, (C1-C18)alkylamino(C6-C20)heteroaryl, (C1-C18)cycloalkylamino(C6-C20)aryl, or (C1-C18)cycloalkylamino(C6-C20)heteroaryl, and their OR8 substutes; R5 is (C1-C18alkoxy, hydrogen, hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or OR8, or R5 and R6 are (C1-C18)dioxy provided that R7 is hydrogen; R6 is hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or ORR, (C1-C18)alkoxy, (C1-C18)alkylamino, or (C1-C18)cycloalkylamino, or R6 and R7 are (C1-C18)dioxy provided that R5 is hydrogen; R7 is hydrogen, halo or OR8, hydroxyl, or O—(C1-C18)alkyl(C6-C20)aryl; and R8 is P(═O)(OH)2, P(═O)(O(C1-C18)alkyl(C6-C20)aryl)2, P(═O)(OH)(OM), or P(═O)(OM)2, P═O(O2M).